ONCR-148

N/A

Report date: 2026/03/19 17:01:27

Base Information

Drug NameONCR-148

Drug Alias NameONCR-148

ClassificationCell and gene therapy > Gene therapyBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[4]

Mechanisms of ActionAnti-CD3Fibroblast activation protein alpha antagonists

TargetsT cell surface glycoprotein CD3Prolyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOncorus Inc

China Registration ClassN/A

Develop Information

Active CompaniesOncorus Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A